Aurobindo Pharma has informed that the officials of the Company will be participating in meetings with various investors. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. This intimation is submitted pursuant to Regulation 30(6) of the Listing Regulations. The schedule of the meeting is attached.
The above information is a part of company’s filings submitted to BSE.